|
|
| Product | Quantum (Rs. Cr) (SEBI) | Quantum (Rs. Cr) (Other FSR) | Long Term Rating | Short Term Rating | Regulated By |
| Bank Loan Ratings | 0.00 | 15.40 | ACUITE BBB | Stable | Reaffirmed | - | RBI |
| Bank Loan Ratings | 0.00 | 15.00 | - | ACUITE A3+ | Reaffirmed | RBI |
| Total Outstanding | 0.00 | 30.40 | - | - | - |
| Total Withdrawn | 0.00 | 0.00 | - | - | - |
| Note:- For activities or ratings of instruments falling under the purview of Financial Sector Regulators other than SEBI, the grievance / dispute redressal mechanisms and investor protection mechanisms provided by SEBI shall not be available. |
|
Rating Rationale |
|
Acuité has reaffirmed the long-term rating of 'ACUITE BBB' (read as ACUITE triple B) on the Rs. 15.40 Cr. bank facilities and the short-term rating of 'ACUITE A3+' (read as ACUITE A three plus) on the Rs. 15.00 Cr. bank facilities of Pharmalab India Private Limited. The outlook is 'Stable'. Rationale for rating reaffirmation The rating derives comfort from PIPL's established presence in both domestic and export markets, supporting stable operating performance, with revenue growth of around 8% in FY26 (Estd) over FY25. The financial risk profile remains moderate, characterized by average net worth, low gearing, and stable debt protection metrics, along with adequate liquidity supported by sufficient net cash accruals against long- term debt obligations and moderate utilization of bank limits. However, the overall credit profile is constrained by intensive working capital requirements, primarily due to high inventory and receivables days. Profitability margins have also moderated owing to reduced exports, higher job work expenses, and further one-time impact of employee incentive payouts in FY26 in addition to regular increments. Going forward, the company’s ability to improve margins, sustain profitability, and efficiently manage its working capital will remain key monitorable factors. |
| About the Company |
|
Pharmalab India Private Limited (PIPL) is a Mumbai-based company incorporated in 2006. The company is managed by a group of experienced directors, namely Mr. Umesh P. Shah, Mr. Karnik K. Parikh, Mr. Rashmikant P. Shah, Mr. Nitin P. Shah, Mr. Kunal U. Shah, Mr. Vishal U. Shah, and Mr. Jay K. Shah. The company caters to both domestic and international markets and exports its products to various countries including Bangladesh, USA, Middle East, and several African nations. The company is primarily engaged in the manufacturing of equipment such as Sterilisers, Multi-Column Distillation Plants, Pure Steam Generators, Filter Presses, and Hospital Sterilisers, which are widely used across industries including pharmaceuticals, chemicals, water treatment, beverages, distilleries, pesticides, food processing, and healthcare. In addition to manufacturing, the company undertakes installation services and annual maintenance contracts (AMC) for its clients. It also carries out trading activities linked to export orders, with trading contributing approximately 20–30% of its overall business operations. |
| Unsupported Rating |
| Not Applicable |
| Analytical Approach |
| Acuité has considered the standalone financial and business risk profiles of PIPL to arrive at the rating. |
| Key Rating Drivers |
| Strengths |
| Experienced management with an established track record of operations |
| Weaknesses |
| Continuous moderation in margins:
|
Rating Sensitivities
| Potential triggers (individual or collective) for an upward rating action: |
|
| Potential triggers (individual or collective) for a downward rating action: |
|
| Liquidity Position |
| Adequate |
|
The liquidity of the company stood adequate marked by net cash accruals (NCA) of Rs. 8.55 crores as against long term debt repayment of Rs. 0.15 crores in FY25. NCA is estimated to be in the range of 8-8.50 crores against the debt repayment of Rs.0.89 crores for FY 26(Estd). Further, PIPL’s NCA is expected to be in the range of Rs.10-11 crores for FY 27 and Fy 28 against debt obligation of Rs.1.5-2 crores for the same period. The current ratio stood healthy at 1.69 times in FY25. Fund based Bank limit utilization (BLU) stood at 45% (based on the closing balance) and 69% (based on the maximum utilization) for six months ending Mar’26. Further, average non fund-based BLU stood at 70-80%. Acuite believes liquidity will be adequate in the medium term supported by steady accruals and absence of major debt funded capex plan. |
| Outlook: Stable |
| |
| Other Factors affecting Rating |
| None |
| Particulars | Unit | FY 25 (Actual) | FY 24 (Actual) |
| Operating Income | Rs. Cr. | 159.61 | 166.26 |
| PAT | Rs. Cr. | 5.73 | 8.85 |
| PAT Margin | (%) | 3.59 | 5.32 |
| Total Debt/Tangible Net Worth | Times | 0.11 | 0.15 |
| PBDIT/Interest | Times | 6.62 | 7.91 |
| Status of non-cooperation with previous CRA (if applicable) |
| Not Applicable |
| Any other information |
| None |
| Applicable Criteria |
|
• Default Recognition :- https://www.acuite.in/view-rating-criteria-52.htm • Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
| Note on complexity levels of the rated instrument |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| Note:- For activities or ratings of instruments falling under the purview of Financial Sector Regulators other than SEBI, the grievance / dispute redressal mechanisms and investor protection mechanisms provided by SEBI shall not be available. |
|
Contacts |
List of instruments and names of regulators of the instruments |
| © Acuité Ratings & Research Limited. All Rights Reserved. | www.acuite.in |
